Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v2-FR
Language French French
Date Updated 2018-02-05 2017-03-31
Drug Identification Number 02234503 02234503
Brand name APO-TERAZOSIN APO-TERAZOSIN
Common or Proper name TERAZOSIN TERAZOSIN
Company Name APOTEX INC APOTEX INC
Ingredients TERAZOSIN TERAZOSIN
Strength(s) 2MG 2MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 500 BTL 500 BTL
ATC code G04CA G04CA
ATC description DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2017-06-15 2017-06-15
Actual discontinuation date 2017-06-30
Remaining supply date 2017-06-15 2017-06-15
Discontinuation status Discontinued To be discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments APO-TERAZOSIN 2 MG TAB 100 BTL is available APO-TERAZOSIN 2 MG TAB 100 BTL is available
Health Canada comments